Document:

FIRST AMENDMENT TO
CREDIT AGREEMENT

          This
First Amendment to Credit Agreement (this “Amendment”) is dated as of November
27, 2007, by and between (i) FIFTH STREET MEZZANINE PARTNERS II, L.P., a
Delaware limited partnership (“Lender”) and (ii) XLNT VETERINARY CARE, INC., a
Delaware corporation (“Borrower”).

RECITALS

          A.
Pursuant to that certain Credit Agreement dated as of June 29, 2007 by and
between Lender and Borrower (the “Credit Agreement”), Borrower has received a
loan from Lender in the maximum principal amount of Three Million Dollars
($3,000,000.00) (the “Original Loan”), as evidenced by that certain Note dated
as of June 29, 2007 executed by Borrower in favor Lender (the “Original Note”).

          B.
Borrower and Lender have agreed to modify the Credit Agreement subject to the
terms and conditions set forth herein below. All capitalized terms used herein
and not otherwise defined shall have the meanings given to such terms in the
Credit Agreement.

AGREEMENT

          NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties agree to amend the Credit Agreement
as follows:

          1.
Loan Amount. The amount of the Loan is hereby increased from Three
Million Dollars ($3,000,000.00)
to Four Million Dollars ($4,000,000.00).

          2.
Note. Borrower’s obligation to repay the Loan, together with interest
thereon, shall be evidenced by that certain Amended and Restated Note of even
date herewith, executed by Borrower and made payable to Lender, in the maximum
principal amount of Four Million Dollars ($4,000,000.00) (the “Amended and Restated Note”). All references in
the Loan Agreement, the Deeds of Trust and the other Loan Documents to the term
“Note” shall mean and be deemed to refer to the Amended and Restated
Note.

          3.
Funding Fee. On or before the date hereof, Borrower shall pay to
Fifth Street Capital LLC a funding fee in the amount of Twenty Thousand Dollars
($20,000.00) in immediately available funds, which fee shall be deemed fully
earned on the date due, and shall not be credited to any other payment required
hereunder.

          4.
Servicing Fee. Concurrently with the execution of this Amendment,
notwithstanding anything to the contrary stated in Section 1.3(b)of the Credit Agreement, Borrower shall
pay Two Hundred Dollars ($200.00) to Fifth Street Capital LLC in addition to
the regular monthly Servicing Fee. Starting on December 1, 2007 and during the
remaining term of the Loan, the Servicing Fee and shall be increased from Five
Hundred Sixty-Two Dollars and 50/100 ($562.50) to Seven Hundred Sixty-Two
Dollars and 50/100 ($762.50) per month.

          5.
Warrant. Borrower shall issue to Lender, as additional
consideration for the Loan and a condition precedent to closing, an additional
warrant exercisable for up to 300 shares of

Series B preferred stock (the “Warrant”), which Warrant will provide (i)
an immediately issued warrant right to purchase up to 150 shares of Series B
preferred stock and (ii) a warrant right to purchase up to 150 shares of Series
B preferred in the event Borrower does not consummate the contemplated SPAC
Merger on or before December 31, 2007.

          6.
Title Policy. Borrower shall cause Lender to receive such assurance as
Lender may require that the validity and lien priority of the Deeds of Trust
have not been and will not be impaired by this Amendment or the transactions
contemplated by it, including CLTA Endorsement No. 108.8 to be attached to the
policies of title insurance delivered to Lender in connection with this
Amendment.

          7.
Closing Date. The closing under this Amendment shall be effective
when the Modification Agreements to the Deeds of Trust (collectively, the
“Modification Agreements”) have recorded in the applicable County and all
conditions and obligations set forth herein have been satisfied by Borrower.

          8.
Costs and Expenses. In accordance with Section 1.3(d) of the
Credit Agreement, Borrower agrees to promptly pay all fees, charges, costs and
expenses (including reasonable attorneys’ fees and expenses incurred by Lender
in connection with any matters contemplated by or arising out of the Loan
Documents), in connection with the examination, review, due diligence
investigation, documentation, negotiation, closing and syndication of the
transactions contemplated herein and in connection with the continued
administration of the Loan Documents including any amendments (including this
Amendment), modifications, subordination or intercreditor agreements, consents
and waivers. Borrower agrees to promptly pay reasonable documentation charges
assessed by Lender for amendments (including this Amendment), modifications,
subordination or intercreditor agreements, waivers, consents and any of the
documentation prepared by Lender’s attorneys. All fees, charges, costs and
expenses for which Borrower is responsible pursuant hereto shall be deemed part
of the Obligations when incurred, payable upon demand and secured by the
Collateral. 

          9.
Covenants of Borrower. Borrower covenants to Lender as follows:

                    a.
Borrower shall cause to be executed, delivered, and performed such additional
agreements, documents, and instruments as reasonably required by Lender to
effectuate the intent of this Amendment.

                    b.
Borrower fully, finally, and forever releases and discharges Lender, together
with their respective successors, assigns, directors, officers, employees,
agents, and representatives from any and all actions, causes of action, claims,
debts, demands, liabilities, obligations, and suits, of whatever kind or
nature, in law or equity (collectively, the “Claim”), that Borrower has or in
the future may have, whether known or unknown, but only with respect to those
Claims for which both of the following are true: (i) the Claim is in respect of
the Loan, the Loan Documents, or the actions or omissions of Lender in respect
of the Loan or the Loan Documents, and (ii) the Claim arises from events
occurring prior to the date of this Amendment. It is the intention of Borrower
that the above release shall be effective as a full and final release of each
and every matter specifically and generally referred to above.

-2-

          10.
Borrower Representations and Warranties. Borrower represents and
warrants to Lender as of the date hereof that:

                    a.
The representations, warranties, certifications and agreements contained in the
Loan Documents are true, complete and accurate in all material respects as of
the date hereof.

                    b.
Both Borrower and, to Borrower’s knowledge, Lender have performed all of their
respective obligations under the Loan Documents and Borrower has no knowledge
of any event which with the giving of notice, the passage of time or both would
constitute a default by Borrower or Lender under the Loan Documents.

                    c.
Borrower has no claim against Lender and no offset or defense to the payment or
performance of the Obligations or any counterclaim or right to rescission to
enforcement of any of the terms of the Loan Documents.

                    d.
No voluntary actions or, to Borrower’s knowledge, involuntary actions are
pending against Borrower, any member of Borrower of the Loan under the
bankruptcy or insolvency laws of the United States or any state thereof.

                    e.
The Loan Documents, as any of the same have been modified, amended and
restated, are the valid, legal and binding obligations of Borrower (as
applicable), enforceable in accordance with their terms.

          11.
Conditions Precedent. Lender shall not be bound by this Amendment
unless and until Lender has received a fully executed original of this
Amendment, the Amended and Restated Note, the Modification Agreements and all
other Loan Documents required by Lender in connection with this Amendment.

          12.
Notices. Borrower’s address for notices in Section 8.3 of the
Credit Agreement is hereby amended as follows:

	
   

  	
   

  	
   

  	
   

  
	
   

  	
  If to Borrower: 

  	
  XLNT Veterinary Care, Inc.

  
	
   

  	
   

  	
  560 South Winchester Boulevard, Suite 500

  
	
   

  	
   

  	
  San Jose, CA 95128

  
	
   

  	
   

  	
  Attn: 

  	
  Robert Wallace, Chairman & CEO

  
	
   

  	
   

  	
  Fax:

  	
  (408) 236-7421

  
	
   

  
	
   

  	
  With a copy to:

  	
  XLNT Veterinary Care, Inc.

  
	
   

  	
   

  	
  560 South Winchester Boulevard, Suite 500

  
	
   

  	
   

  	
  San Jose, CA 95128

  
	
   

  	
   

  	
  Attn:

  	
  Gregory J. Eisenhauer,
  CFO

  
	
   

  	
   

  	
  Fax:

  	
  (408) 521-0428 

  

          13.
Ratification of Loan Documents and Collateral. Borrower hereby ratifies
and affirms each of the Loan Documents, as amended hereby, and agrees to
perform each obligation set forth in each of the Loan Documents, as amended
hereby. Except as specifically modified and amended herein, all terms,
conditions and covenants contained in the Credit Agreement and the other Loan
Documents shall remain in full force and effect. Any property or rights to or

-3-

interests in property granted as security in the Loan
Documents, including the Collateral, shall remain as security for the Loan and
the obligations of Borrower under the Loan Documents. 

          14.
Miscellaneous.

                    a.
The Loan Documents as modified herein contain the entire understanding and
agreement of Borrower and Lender with respect to the Loan and supersede all
prior representations, warranties, agreements, arrangements, and
understandings. No provision of the Loan Documents as modified may be changed,
discharged, supplemented, terminated, or waived except in a writing signed by
Lender and Borrower. 

                    b.
All references in the Loan Documents to the Credit Agreement shall mean the
Credit Agreement as hereby modified and amended. This Amendment shall also
constitute a Loan Document and all terms and conditions of the Credit Agreement
(as modified herein) including, without limitation, events of default, maturity
dates and the miscellaneous provisions set forth therein, including without
limitation, consent to jurisdiction, applicable law, and waiver of jury are
incorporated herein as though set forth in full and Lender shall be entitled to
the benefits thereof with respect to this Amendment. 

                    c.
This Amendment may be executed in any number of counterparts with the same
effect as if all parties hereto had signed the same document. All such
counterparts shall be construed together and shall constitute one instrument,
but in making proof hereof it shall only be necessary to produce one such
counterpart.

[Signature Page
Follows]

-4-

          IN
WITNESS WHEREOF, the undersigned have entered into this Amendment as of the
date first above written.

	
   

  	
   

  	
   

  
	
   

  	
  BORROWER:

  
	
   

  	
   

  	
   

  
	
   

  	
  XLNT VETERINARY CARE, INC.,

  a Delaware corporation

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  
	
   

  	
 

  
	
   

  	
  Name:

  
	
   

  	
 

  
	
   

  	
  Title:

  
	
   

  	
 

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  LENDER:

  
	
   

  	
   

  
	
   

  	
  FIFTH STREET MEZZANINE PARTNERS II,
L.P.,
  a Delaware limited partnership

  
	
   

  	
   

  
	
   

  	
  By:

  	
  Fifth Street Mezzanine Partners II GP, LLC,

  a Delaware limited liability company,

  its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  
	
   

  	
 

  
	
   

  	
  Name: 

  	
  Bernard D. Berman

  
	
   

  	
  Title:

  	
  Executive Vice President and SecretaryExhibit 10.38

CO-SALE AGREEMENT

This CO-SALE AGREEMENT (this “Agreement”) is entered into as of September 11, 2006, by and among Echo Healthcare Acquisition Corp., a Delaware corporation (“Parent”), and each of the stockholders of the Company signatory hereto (each, a “Stockholder,” and together, the “Stockholders”).

W I T N E S S E T H:

WHEREAS, on the date hereof, Parent, Pet DRx Acquisition Company, a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and XLNT Veterinary Care, Inc., a Delaware corporation (the “Company”), are entering into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into the Company and the Company will continue its existence as the surviving corporation (the “Merger”);

WHEREAS, in connection with the Merger, each of the Stockholders shall receive shares of common stock of Parent, par value $.0001 per share (the “Parent Common Stock”);

WHEREAS, as a condition to the Closing of the Merger, the Company has required that each of the Stockholders enter into this Agreement; and

WHEREAS, capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in the Merger Agreement.

NOW, THEREFORE, in consideration of the foregoing and the mutual premises, representations, warranties, covenants and agreements contained in this Agreement, the parties, intending to be legally bound, hereby agree as follows:

AGREEMENT

	
             
 	
            1.
 	
            Restrictions on Transfer and Short Sales.
 

	
             
 	
            (a)
 	
            Each Stockholder hereby:
 

 (i)        agrees that such Stockholder will not, directly or indirectly, during the Restricted Period (as defined below), (A) offer, sell, contract to sell, grant any option for the purchase of, pledge, assign, lend or otherwise transfer or dispose of any Parent Common Stock that such Stockholder receives as a result of the Merger at the time of the Closing (the “Restricted Securities”) or (B) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic characteristics of ownership of the Restricted Securities, whether any such transaction described in clauses (A) or (B) above is to be settled by delivery of Restricted Securities, in cash or otherwise; and

(ii)       authorizes Parent during the Restricted Period to cause Parent’s transfer agent to place a legend on any certificates representing the Restricted Securities and to decline to 

 

transfer and to note stop transfer restrictions on the transfer books and records of Parent with respect to those Restricted Securities, unless the transfer is permitted by this Agreement.

(b)       For purposes of this Agreement, “Restricted Period” shall mean the date commencing on the Closing Date (inclusive of such date) and ending on the date that is five hundred forty (540) days following the Closing Date; provided, that if Parent (i) has the right to redeem its public warrants issued pursuant to its Prospectus dated March 17, 2006, the Restricted Period shall terminate on the date specified for such redemption or (ii) conducts an underwritten public offering of Parent Common Stock following the Closing Date in which any Stockholder elects to participate and the underwriter thereof consents to such Stockholder’s participation in such offering, then the Restricted Period shall terminate with respect to such Stockholder on
the date that the registration statement filed with respect thereto is declared effective by the Securities and Exchange Commission.

(c)       Notwithstanding the foregoing, following the date that is one hundred eighty (180) days following the Closing Date (the “Initial Release Date”), if as of any trading day the last sales price of Parent Common Stock equaled or exceeded $9.00 per share (subject to adjustment for stock splits, combinations and like events) on each of the previous twenty (20) trading days, then the restrictions in Section 1(a)(i)(A) shall not apply on such trading day. 

(d)       In addition to the foregoing, in the event that all or any portion of the shares of Parent Common Stock held in escrow pursuant to that certain Stock Escrow Agreement dated as of March 22, 2006 among Parent, Corporate Stock Transfer, Inc. and the founding stockholders of Parent are released from the terms of such Stock Escrow Agreement prior to the end of the Restricted Period for any reason, then the Restricted Securities of each Stockholder shall be released from the provisions of this Agreement on the same schedule.

2.         Co-Sale.   Notwithstanding the restrictions contained in Section 1 hereof, if at any time following the Initial Release Date (but during the Restricted Period), any Stockholder (a “Proposed Seller”) desires to sell, transfer or otherwise dispose of, in a privately negotiated transaction (each, a “Transfer”), all or any portion of the Restricted Securities held by such Proposed Seller, the Proposed Seller shall deliver written notice (the “Co-Sale Notice”) of the terms and conditions (including price per share) of the proposed Transfer to each other Stockholder (the
“Co-Sale Rights Holders”) informing each Co-Sale Rights Holder of the number of Restricted Securities the Proposed Seller holds and intends to Transfer (the “Co-Sale Shares”) to the proposed transferee or transferees (the “Proposed Transferee”).  Each Co-Sale Rights Holder shall have the right, exercisable upon written notice to the Proposed Seller within thirty (30) days after the giving of the Co-Sale Notice by the Proposed Seller, to participate in the Proposed Seller’s Transfer of Co-Sale Shares upon the terms and conditions set forth in the Co-Sale Notice (including price per share).  The delivery by a Co-Sale Rights Holder of the notice of election under this paragraph shall constitute an irrevocable commitment by such Co-Sale Rights Holder to Transfer such shares upon the terms and conditions set
forth in the Co-Sale Notice.  To the extent one or more of the Co-Sale Rights Holders exercises such right of participation in accordance with the terms and conditions set forth below, the number of Restricted Securities that the Proposed Seller may Transfer to the Proposed Transferee shall be correspondingly reduced.  The right of participation of each of the Co-Sale Rights Holders shall be subject to the following terms and conditions:

 

	
             
 	
            -
 

(a)       Each of the Co-Sale Rights Holders may elect to Transfer all or any portion of that number of Restricted Securities held by such Co-Sale Rights Holder equal to the product obtained by multiplying (i) the aggregate number of Co-Sale Shares by (ii) a fraction, (A) the numerator of which is the number of Restricted Securities at the time owned by such Co-Sale Rights Holder and (B) the denominator of which is the total number of Restricted Securities held by the Proposed Seller and by each other Co-Sale Rights Holder that has exercised its rights of co-sale hereunder to participate in the Transfer.

(b)       Each of the exercising Co-Sale Rights Holders shall effectuate the Transfer by promptly delivering to the Proposed Seller for Transfer to the Proposed Transferee one or more certificates, properly endorsed for Transfer, which represent the number of Restricted Securities that such Co-Sale Rights Holder elects to Transfer.

(c)       The stock certificates that the participating Co-Sale Rights Holders deliver to the Proposed Seller shall be Transferred by the Proposed Seller to the Proposed Transferee in consummation of the Transfer of the securities pursuant to the terms and conditions specified in the Co-Sale Notice to the Co-Sale Rights Holders, and the Proposed Seller shall promptly thereafter remit to each Co-Sale Rights Holder that portion of the proceeds to which such Co-Sale Rights Holder is entitled by reason of its participation in such Transfer.  To the extent that any Proposed Transferee prohibits such assignment or otherwise refuses to purchase securities from any Co-Sale Rights Holder exercising its rights of co-sale hereunder, the Proposed Seller shall not Transfer to such Proposed Transferee any securities unless and until, simultaneously with such
Transfer, the Proposed Seller shall purchase such securities from such Co-Sale Rights Holder for the same consideration and on the same terms and conditions as the proposed Transfer described in the Co-Sale Notice.

3.         Certain Permitted Transfers.  Notwithstanding anything to the contrary contained herein, any Stockholder may transfer all or part of his or its Restricted Securities (i) in case of death, by way of either testamentary provisions or mandatory provisions of law, (ii) as a bona fide gift or gifts, provided that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein and (iii) to any immediate family member or any trust, family limited partnership or similar entity primarily for the direct or indirect benefit of such Stockholder and/or the immediate family members of such Stockholder, provided, that the immediate family member, trustee of the trust, family
limited partnership or other transferee entity agrees to be bound in writing by the restrictions set forth herein; and provided, further, that any such transfer shall not involve a disposition for value.  For purposes of this Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin (including, without limitation, lineal descendants, stepchildren, father, mother, brother or sister of any Stockholder or such Stockholder’s spouse).   In addition to the foregoing limitations, in the event that any Stockholder is an entity rather than an individual, this Agreement will not prevent any transfer of any or all of the Restricted Securities to the stockholders of such entity, if it is a corporation, to the members of such entity, if it is a limited liability company or to the partners of such entity, if it is a
partnership; provided, however, that in each such case, it shall be a condition to the transfer that such transferee agrees to be bound in writing by the restrictions set forth herein.

 

	
             
 	
            -
 

4.         Representations.  Each Stockholder, severally and not jointly (as to itself or himself), represents, warrants, agrees and acknowledges that:

(a)       Such Stockholder has full legal capacity and power and authority to enter into this Agreement and to carry out such Stockholder’s obligations hereunder.

(b)       This Agreement has been duly executed and delivered by such Stockholder and, assuming due authorization, execution and delivery by the other parties hereto, this Agreement constitutes the legal, valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms.

(c)       The execution and delivery of this Agreement by such Stockholder does not, and the performance of this Agreement by such Stockholder will not, (i) conflict with or violate any Legal Requirement applicable to such Stockholder or by which any property or asset of such Stockholder is bound or affected or (ii) result in any breach of or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to any other Person any right of termination, amendment, acceleration or cancellation of, or result in the creation of any encumbrance on any property or asset of such Stockholder pursuant to any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation.

(d)       The execution and delivery of this Agreement by such Stockholder does not, and the performance of this Agreement by such Stockholder will not, require any consent, approval, authorization or permit of, or filing with or notification to, any governmental or regulatory authority, domestic or foreign, except (i) for compliance with applicable requirements, if any, under the Securities Exchange Act of 1934, as amended, and (ii) where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or materially delay the performance by such Stockholder of such Stockholder’s obligations under this Agreement.

(e)       Such Stockholder understands that the obligations set forth in this Agreement are irrevocable on the part of such Stockholder and shall survive such Stockholder’s death or incapacity.  Any obligations created by this Agreement shall be binding upon the heirs, devisees, personal representatives, successors and assigns of each Stockholder.

5.         Further Assurances.  Each Stockholder agrees that, upon request, such Stockholder will take any further action and execute any additional documents or instruments as may be reasonably necessary in connection with the enforcement of this Agreement or to otherwise effectuate the intent of this Agreement.

	
             
 	
            6.
 	
            Term; Termination.
 

 (a)       This Agreement shall become effective upon the occurrence of the Effective Time of the Merger; provided, however, that if the Merger Agreement is terminated in accordance with its terms, then upon such termination of the Merger Agreement, this Agreement shall terminate and be of no further force or effect as if this Agreement were never executed and delivered.

 

	
             
 	
            -
 

(b)       Unless earlier terminated as provided in paragraph (a) above, this Agreement (i) may be terminated at any time upon the written consent of the Stockholders holding at least 51% of the Restricted Securities then held by all of the Stockholders and (ii) shall terminate and be of no further force or effect (A) upon the end of the Restricted Period and (B) in the event of a Change of Control (as defined below). 

(b)       This Agreement shall terminate with respect to Robert Wallace (the “Executive”) upon the termination by Parent of the Executive without “Cause” or the resignation by the Executive for “Good Reason” (as each such term is defined in the Employment Agreement between Parent and the Executive).

(c)       For purposes of this Agreement, “Change of Control” shall mean (i) the sale of all, or substantially all, of the Parent’s assets in any single transaction or series of related transactions; (ii) the acquisition by any one person, single entity or group within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, of Parent’s common stock possessing a majority of the ordinary voting power to elect directors of Parent; (iii)  any merger or consolidation of Parent with or into another corporation (regardless of which entity is the surviving corporation) if, after giving effect to such merger or consolidation the holders of Parent’s voting securities immediately prior to the merger or consolidation own voting securities of the surviving
or resulting corporation representing less than a majority of the ordinary voting power to elect directors of the surviving or resulting corporation; or (iv)  a liquidation or dissolution of Parent.

	
             
 	
            7.
 	
            Miscellaneous.
 

 (a)       This Agreement shall be governed by and interpreted and construed in accordance with the laws of the State of New York applicable to contracts formed and to be performed entirely within the State of New York, without regard to the conflicts of law provisions thereof to the extent such principles or rules would require or permit the application of the laws of another jurisdiction.  Each of the parties hereto (i) consents to submit itself to the personal jurisdiction of the United States District Court for the Southern District of New York or any court of the State of New York located in such district in the event any dispute arises out of this Agreement or any of the transactions contemplated by this Agreement, (ii) agrees that it will not attempt to deny or defeat such personal jurisdiction or venue by motion or other request for leave from
any such court and (iii) agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated by this Agreement in any court other than such courts sitting in the State of New York.

(b)       No term or provision of this Agreement may be amended, changed, waived, altered or modified except by written instrument executed and delivered by the Stockholders holding at least 51% of the Restricted Securities then held by all of the Stockholders.  No party may assign either this Agreement or any of its rights, interests or obligations hereunder without the prior written consent of each of the other parties hereto. Subject to the preceding sentence, this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, devisees, personal representatives, successors and permitted assigns.

 

	
             
 	
            -
 

(c)       This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.  This Agreement or any counterpart may be executed and delivered by facsimile copies, each of which shall be deemed an original.

(d)       If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the substance of the transactions contemplated hereby is not affected in any manner adverse to any party hereto.  Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties hereto as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible.

(e)       Any and all remedies herein expressly conferred upon a party hereto will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party hereto of any one remedy will not preclude the exercise of any other remedy.  The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.  It is accordingly agreed that the parties hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the state courts of the State of New York sitting in the City of New York or any court of the United States located in the City of New
York, this being in addition to any other remedy to which such party is entitled at law or in equity.

[Signature pages follow]

 

	
             
 	
            -
 

IN WITNESS WHEREOF, this Co-Sale Agreement has been executed as of the day and year first above written.

	
             
 	
            ENTITY STOCKHOLDER SIGNATURES:
 

 

 

	
             
 	
            /s/ Donald W. Hughes
 

Entity Name:  Camden Partners Strategic Fund, III, L.P.

	
             
 	
            Name of Signatory:  Donald W. Hughes
 

	
             
 	
            Title of Signatory: Member
 

 

 

	
             
 	
            /s/ Donald W. Hughes
 

Entity Name: Camden Partners Strategic Fund III-A, L.P.

	
             
 	
            Name of Signatory:  Donald W. Hughes
 

	
             
 	
            Title of Signatory: Member
 

 

 

	
             
 	
            /s/ Paula Semelmacher
 

	
             
 	
            Entity Name: Galen Employee Fund IV, L.P.
 

	
             
 	
            Name of Signatory:  Paula Semelmacher
 

Title of Signatory: Vice President, Wesson Enterprises, Inc.; General Partner

 

	
             
 	
            /s/ Zubeen Shroff
 

	
             
 	
            Entity Name: Galen Partenersm Int’l IV, L.P.
 

	
             
 	
            Name of Signatory:  Zubeen Shroff
 

	
             
 	
            Title of Signatory: Managing Director
 

 

 

	
             
 	
            /s/ Zubeen Shroff
 

	
             
 	
            Entity Name: Galen Partners IV, L.P.
 

	
             
 	
            Name of Signatory:  Zubeen Shroff
 

	
             
 	
            Title of Signatory: Managing Director
 

 

 

	
             
 	
            INDIVIDUAL STOCKHOLDER SIGNATURE:
 

 

 

	
             
 	
            /s/ J. David Reed
 

	
             
 	
            Name:  J. David Reed
 

 

 

	
             
 	
            /s/ Zubeen Shroff
 

	
             
 	
            Name:  Zubeen Shroff
 

 

	
             
 	
            -
 

 

	
             
 	
            /s/ Robert Wallace
 

	
             
 	
            Name:  Robert Wallace
 

 

 

Acknowledged and Agreed:

 

ECHO HEALTHCARE ACQUISITION CORP.

 

	
            By: /s/ Gene E. Burleson
 

Name: Gene E. Burleson

	
            Title:  
 	
            CEO
 

 

 

	
             
 	
            -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]